Skip to content
Review Open access

Current challenges and emerging therapeutic strategies in lung cancer care: Insights from Bridging the Gaps 2025

Sep 2026 · Cancer · Vol 132 · 1 citation · 106 references
Medicine

TL;DR

A multidisciplinary panel of oncology experts convened to review current evidence gaps, controversies, and unmet needs in the management of lung cancer, highlighting the need for prospective, head‐to‐head clinical trials.

Abstract

Recent years have seen substantial advances in lung cancer management, with therapeutic options expanding rapidly through the integration of targeted therapies, immunotherapies, antibody–drug conjugates, and novel, immune‐engaging agents. Although outcomes have improved for selected patients with non–small cell lung cancer and small cell lung cancer, the increasing number of regimens has amplified clinical complexity, with persistent evidence gaps, limited head‐to‐head comparisons, and underrepresentation of key subgroups in trials. Emerging genomic tools and novel therapeutic modalities provide opportunities to further improve patient outcomes but also add to the challenges of clinical decision‐making. To address these issues, a multidisciplinary panel of oncology experts, primarily based in the United States, convened to review current evidence gaps, controversies, and unmet needs in the management of lung cancer. Key areas were identified in treatment selection and sequencing as well as the management of high‐risk subtypes, highlighting the need for prospective, head‐to‐head clinical trials. Findings from this panel will inform a 2026 follow‐up conference in which a modified Delphi method will be used to develop formal consensus recommendations to provide actionable guidance for practicing clinicians.

Read PDF

Similar papers

Review Sep 2026

Emerging Therapies in Lung Cancer: A Review on Targeted and Immune Based Interventions.

This review encapsulates significant developments in molecularly targeted agents and immune checkpoint inhibitors, emphasising their clinical efficacy, resistance mechanisms, and innovative therapeutic combinations, and reviews pivotal clinical trials and newly filed patents.

K. C. Geervani, R. Maddileti, Kalpi Sania Kausar et al. · 0 citations
Open access Oct 2026

Early-Phase Drug Development in Rare Cancers: A Decade of Progress and Future Directions

Rare cancers represent a substantial health burden, comprising 25% of cancer mortality. Early-phase oncology trials are essential for rare cancers, where limited patient numbers, biological heterogeneity, and the absence of established standards of care necessitate innovative approaches to drug development. Advances in...

Y. Myat, K. Thein, Lujain Mahmood et al. · 0 citations
Review Open access Sep 2026

Recent advances in targeted therapies and immunotherapies for triple-negative breast cancer

This comprehensive review explores advancements in the treatment of Triple-Negative Breast Cancer, emphasizing the transformative impact of targeted therapies and immunotherapies and envisions a future where targeted and immune-based interventions redefine TNBC treatment, offering new hope for patients and clinicians a...

Gowhar Rashid, D. Elsori, Zainab Naqvi et al. · 0 citations
Review Aug 2026

The emerging trends in prostate cancer treatment: a systematic review of the literature.

This Systematic review provides a comprehensive framework for understanding current therapeutic options and future directions in prostate cancer treatment. It highlights ongoing efforts, focusing on AR signaling inhibitors (ARSi) and novel molecularly targeted therapies. Using PRISMA-ScR guidelines, we conducted a comp...

Syeda Ayesha Fatima, K. Haider, Sara Qutubuddin et al. · 1 citation
Review Open access Oct 2026

Biomarker Integration in the Perioperative Management of Early-Stage Non-Small-Cell Lung Cancer

The concept of personalized medicine has tremendous appeal—tailoring diagnosis and treatment to an individual, rather than a “one-size-fits-all” approach. The management of non-small-cell lung cancer (NSCLC) has rapidly evolved toward strategies increasingly guided by tumor biology and precision oncology. The safety an...

Emily P. Rabinovich, Linda W. Martin · 0 citations
Review Sep 2026

Translational Horizons in Targeted Oncology: Mechanistic Insights, Therapeutic Innovations, and Clinical Impact.

The identification of new molecular targets and the growth of personalized therapies for cancer depend on current studies, and it is believed that new advances in molecular science will contribute to the development of innovative and successful methods for therapy, and eventually decrease the prevalence of malignancies...

Hardha Balachandran, Gowramma Byran, S. Murugesan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.